PMID- 17158764
OWN - NLM
STAT- MEDLINE
DCOM- 20070301
LR  - 20161124
IS  - 1351-0088 (Print)
IS  - 1351-0088 (Linking)
VI  - 13
IP  - 4
DP  - 2006 Dec
TI  - Natural course of small, asymptomatic neuroendocrine pancreatic tumours in 
      multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study.
PG  - 1195-202
AB  - Endoscopic ultrasound (EUS) enables detection and localization of pancreatic 
      neuroendocrine tumours. Even small tumours down to a diameter of 1-2 mm can be 
      visualized. Since such small tumours usually cannot be detected by computed 
      tomography (ct), magnetic resonance imaging (mri) and somatostatin receptor 
      scintigraphy (srs), and experience with EUS imaging is limited, there is no clear 
      evidence for clinical management in multiple endocrine neoplasia type 1 (MEN1). 
      Knowledge about the natural course of growth and metastatic distribution is 
      mandatory to come to appropriate clinical decisions and guidelines. This 
      prospective study was aimed to assess the natural course of small (<15 mm) 
      neuroendocrine pancreatic tumours without clinical symptoms due to endocrine 
      activity or mechanical problems and without clear indication for surgical therapy 
      in MEN1 by EUS. A total of 82 asymptomatic tumours<15 mm (5.9+/-3.2 mm diameter 
      at baseline) in 20 patients with MEN1-disease (8 female/12 male, 43+/-13 years) 
      were studied over a period of 20+/-12 months (33.8 patient years, 106.7 tumour 
      years) by EUS. Change in largest diameter of each tumour and annual tumour 
      incidence rate in the patients' cohort were calculated. Increase of largest 
      tumour diameter was found to be 1.3+/-3.2% per month, annual tumour incidence 
      rate 0.62 new tumours per patient year. In one patient, rapid progressive 
      pancreatic manifestation of MEN1 was observed. There was no evidence in ct and/or 
      srs and/or mri for metastatic disease in all patients. Only 4/84 (4.8%) 
      pancreatic tumours could be visualized by computed tomography, 5/79 (6.3%) by 
      somatostatin receptor imaging and 4/39 (10.3%) by magnetic resonance imaging. 
      Small asymptomatic neuroendocrine pancreatic tumours in MEN1 usually seem to grow 
      slowly. Annual tumour incidence rate is low. However, faster growing tumours and 
      patients with rapidly progressive disease can be observed. Risk for obvious 
      metastatic disease from asymptomatic neuroendocrine pancreatic tumours<15 mm in 
      MEN1 seems to be low.
FAU - Kann, P H
AU  - Kann PH
AD  - Division of Endocrinology and Diabetology, Department of Surgery, Phillipp's 
      University, Marburg, Germany. Kannp@med.uni-marburg.de
FAU - Balakina, E
AU  - Balakina E
FAU - Ivan, D
AU  - Ivan D
FAU - Bartsch, D K
AU  - Bartsch DK
FAU - Meyer, S
AU  - Meyer S
FAU - Klose, K-J
AU  - Klose KJ
FAU - Behr, Th
AU  - Behr T
FAU - Langer, P
AU  - Langer P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Receptors, Somatostatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Neuroendocrine/*diagnostic imaging/pathology
MH  - Cohort Studies
MH  - *Endosonography
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*diagnostic imaging
MH  - Pancreatic Neoplasms/*diagnostic imaging/pathology
MH  - Positron-Emission Tomography
MH  - Prospective Studies
MH  - Radiography
MH  - Receptors, Somatostatin/metabolism
MH  - Tomography, Emission-Computed
EDAT- 2006/12/13 09:00
MHDA- 2007/03/03 09:00
CRDT- 2006/12/13 09:00
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2007/03/03 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
AID - 13/4/1195 [pii]
AID - 10.1677/erc.1.01220 [doi]
PST - ppublish
SO  - Endocr Relat Cancer. 2006 Dec;13(4):1195-202. doi: 10.1677/erc.1.01220.